HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kyowa Hakko Expands Probiotic Supplies With ‘Dead’ Ingredient To Battle Eye Fatigue

Executive Summary

Kyowa Hakko unveils supplement ingredient Eyemuse, a heat-treated “paraprobiotic” found to reduce eye fatigue, filter blue light and support a balanced immune response. CRN campaign educates retailers, consumers about probiotics and helps retailers improve handling of the products.

You may also be interested in...



Kyowa Hakko’s Immuse Paraprobiotic Works In Small Intestine For Immune Support

Kyowa Hakka offers Immuse paraprobiotic to activate the plasmacytoid dendritic cells in small intestine while most other probiotics work in large intestine. GOLO's Go-Digest supplement promotes healthy microflora in gut to support overall health.

‘Uniquely Positioned’ In Probiotics, IFF Emphasizes Ingredients For Women's, Cognitive, Skin Health

Jennifer Montgomery, IFF’s probiotics marketing manager for the Americas, responds to HBW Insight questions about the firm’s plans to deliver probiotics ingredients and technologies following the recent closing of its acquisition of DuPont Nutrition & Biosciences through a merger agreement.

On VMS Product Delivery Format, CRN Survey Shows US Consumers Prioritize Ease Of Swallowing

Trade group recently published survey results also show although the total of US consumers using supplements in 2020, 73%, is down 4 percentage points from 2019, a substantial segment of users are taking more products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel